5-Amino-1MQ vs SLU-PP-332

A first-in-class NNMT (nicotinamide N-methyltransferase) inhibitor that redirects cellular energy toward metabolic acceleration. Early clinical pipeline; widely used in biohacker fat-loss protocols.

An ERRα/β/γ pan-agonist that mimics the metabolic effects of exercise by activating oxidative-phosphorylation gene programs. Early-stage — animal data extraordinary, human data pending.

5-Amino-1MQ inhibits NNMT, reducing methyl-nicotinamide accumulation and increasing cellular NAD+/SAM levels. The downstream effect is improved metabolic throughput and reduced fat storage.

SLU-PP-332 activates oestrogen-related receptors (ERRα, ERRβ, ERRγ), upregulating the gene set responsible for fat oxidation, mitochondrial biogenesis, and skeletal-muscle endurance — effectively an "exercise mimetic."

50–150 mg daily oral (research protocols)

25–50 mg daily oral (preclinical extrapolation)

Short — typically daily dosing

Not well characterised

Oral

Oral, Subcutaneous

investigational

investigational

Not yet listed

Not yet listed